NASDAQ · GRPH
Healthcare · Biotechnology
$3.18
Down-$0.09 (-2.75%)
Updated Aug 14, 2026, 4:38 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
GRPH does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning GRPH.
GRPH research
Company profile and research snapshot.
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 21, 2023 | RBC Capital | Sector Perform | — |
| Feb 23, 2023 | B of A Securities | Underperform | — |
| Feb 23, 2023 | Cantor Fitzgerald | Neutral | — |
| Feb 23, 2023 | Cowen & Co. | Market Perform | — |
| Feb 3, 2023 | Morgan Stanley | Equal-Weight | — |
No generated briefing is available yet.
Zacks Investment Research · Nov 16, 2023
Graphite Bio, Inc. (GRPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research · May 10, 2023
Graphite Bio (GRPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks Investment Research · Apr 24, 2023
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Benzinga · Jan 25, 2023
Analysts have provided the following ratings for Graphite Bio (NASDAQ:GRPH) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 0 0 Last 30D 0 0 0 0 0 1M Ago 0 0 4 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 These 4 analysts have an average price target of $4.0 versus the current price of Graphite Bio at $1.92, implying upside. Below is a summary of how these 4 analysts rated Graphite Bio over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts ...Full story available on Benzinga.com
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GRPH.
No results
No recent SID articles mention GRPH.
